This clinical trial investigated the benefit of IFN-γ–DExs as an adjuvant to ameliorate the rate of progression-free survival (PFS) of NSCLC patients previously treated with first-line platinum-based chemotherapy. This evidence concerns the gene IFNG and non-small cell lung carcinoma.